Search Results

Mitsubishi Electric Corporation announced that Dr. Shumpei Kameyama of Mitsubishi Electric’s Information Technology R&D Center and Dr. Jonathan Le Roux of Mitsubishi Electric Research Laboratories, Inc. have been awarded the title of IEEE Fellow.

Mitsubishi Tanabe Pharma America, Inc. is aware of recent external challenges facing the amyotrophic lateral sclerosis treatment landscape.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the two-year launch anniversary of RADICAVA ORS ® (edaravone) in the U.S.

Mitsubishi Electric Corporation, Okayama University and Osaka University’s Graduate School of Engineering announced that they have developed a magnetic particle imaging device capable of sensitive imaging of magnetic particles in an area equivalent in size to that of the human brain, in a project supported by the Japan Agency for Medical Research and Development.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on investigational ND0612 in Parkinson’s disease (PD) will be shared at the 10th Congress of the European Academy of Neurology (EAN), being held in Helsinki, Finland, June 29 – July 2.

Mitsubishi Tanabe Pharma America, Inc. is celebrating its eight-year anniversary of being established in the United States.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from two studies of RADICAVA® (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson’s disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson’s Disease and Related Disorders, being held in Lisbon, Portugal.